Effect of nitric oxide on strophanthidin-induced ventricular tachycardia

Y. J. Chen, C. F. Tsai, Chuen Wang Chiou, P. Chan, S. A. Chen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Nitric oxide (NO) has been demonstrated to have several effects on the heart. Through the stimulation of guanylate cyclase, NO increases cyclic GMP and decreases intracellular calcium. The purpose of this study was to evaluate the effects of NO on ventricular arrhythmia induced by strophanthidin in guinea pigs and dogs. In experiment 1, after strophanthidin-induced ventricular tachycardia, guinea pigs received different doses of L-arginine (0, 25, 50, 100, 200, and 400 mg/kg; n = 10 for each dose), 200 mg/kg L-arginine combined with 100 mg/kg NG-nitro-L-arginine methylester (L-NAME, n = 10), or 200 mg/kg D-arginine (n = 10). In experiment 2, after strophanthidin-induced ventricular tachycardia, dogs (n = 7) received 200 mg/kg L-arginine. By 12-lead ECG, monophasic action potentials in left and right ventricles were recorded throughout the study. In experiment 1, guinea pigs which received 200 mg/kg or 400 mg/kg L-arginine had greater incidences of ventricular tachycardia termination (60 and 80%, respectively) than those which received 0, 25, 50, and 100 mg/kg L-arginine (0, 0, 20, and 30%, respectively), those which received L-arginine with L-NAME (0%), and those which received D-arginine (0%). In experiment 2, 5 (71%) of the dogs had successful termination of ventricular tachycardia. These findings suggest that L-arginine was effective in treating strophanthidin-induced ventricular tachycardia in vivo and that the underlying mechanism is through a NO pathway.

Original languageEnglish
Pages (from-to)213-217
Number of pages5
JournalPharmacology
Volume62
Issue number4
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Strophanthidin
Ventricular Tachycardia
Arginine
Nitric Oxide
Guinea Pigs
NG-Nitroarginine Methyl Ester
Dogs
Heart Ventricles
Guanylate Cyclase
Nitroarginine
Cyclic GMP
Action Potentials
Cardiac Arrhythmias
Electrocardiography

Keywords

  • Nitric oxide
  • Strophanthidin
  • Ventricular arrhythmia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of nitric oxide on strophanthidin-induced ventricular tachycardia. / Chen, Y. J.; Tsai, C. F.; Chiou, Chuen Wang; Chan, P.; Chen, S. A.

In: Pharmacology, Vol. 62, No. 4, 2001, p. 213-217.

Research output: Contribution to journalArticle

Chen, Y. J. ; Tsai, C. F. ; Chiou, Chuen Wang ; Chan, P. ; Chen, S. A. / Effect of nitric oxide on strophanthidin-induced ventricular tachycardia. In: Pharmacology. 2001 ; Vol. 62, No. 4. pp. 213-217.
@article{cbd122e245404d92b57d854f2533d6d4,
title = "Effect of nitric oxide on strophanthidin-induced ventricular tachycardia",
abstract = "Nitric oxide (NO) has been demonstrated to have several effects on the heart. Through the stimulation of guanylate cyclase, NO increases cyclic GMP and decreases intracellular calcium. The purpose of this study was to evaluate the effects of NO on ventricular arrhythmia induced by strophanthidin in guinea pigs and dogs. In experiment 1, after strophanthidin-induced ventricular tachycardia, guinea pigs received different doses of L-arginine (0, 25, 50, 100, 200, and 400 mg/kg; n = 10 for each dose), 200 mg/kg L-arginine combined with 100 mg/kg NG-nitro-L-arginine methylester (L-NAME, n = 10), or 200 mg/kg D-arginine (n = 10). In experiment 2, after strophanthidin-induced ventricular tachycardia, dogs (n = 7) received 200 mg/kg L-arginine. By 12-lead ECG, monophasic action potentials in left and right ventricles were recorded throughout the study. In experiment 1, guinea pigs which received 200 mg/kg or 400 mg/kg L-arginine had greater incidences of ventricular tachycardia termination (60 and 80{\%}, respectively) than those which received 0, 25, 50, and 100 mg/kg L-arginine (0, 0, 20, and 30{\%}, respectively), those which received L-arginine with L-NAME (0{\%}), and those which received D-arginine (0{\%}). In experiment 2, 5 (71{\%}) of the dogs had successful termination of ventricular tachycardia. These findings suggest that L-arginine was effective in treating strophanthidin-induced ventricular tachycardia in vivo and that the underlying mechanism is through a NO pathway.",
keywords = "Nitric oxide, Strophanthidin, Ventricular arrhythmia",
author = "Chen, {Y. J.} and Tsai, {C. F.} and Chiou, {Chuen Wang} and P. Chan and Chen, {S. A.}",
year = "2001",
doi = "10.1159/000056097",
language = "English",
volume = "62",
pages = "213--217",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Effect of nitric oxide on strophanthidin-induced ventricular tachycardia

AU - Chen, Y. J.

AU - Tsai, C. F.

AU - Chiou, Chuen Wang

AU - Chan, P.

AU - Chen, S. A.

PY - 2001

Y1 - 2001

N2 - Nitric oxide (NO) has been demonstrated to have several effects on the heart. Through the stimulation of guanylate cyclase, NO increases cyclic GMP and decreases intracellular calcium. The purpose of this study was to evaluate the effects of NO on ventricular arrhythmia induced by strophanthidin in guinea pigs and dogs. In experiment 1, after strophanthidin-induced ventricular tachycardia, guinea pigs received different doses of L-arginine (0, 25, 50, 100, 200, and 400 mg/kg; n = 10 for each dose), 200 mg/kg L-arginine combined with 100 mg/kg NG-nitro-L-arginine methylester (L-NAME, n = 10), or 200 mg/kg D-arginine (n = 10). In experiment 2, after strophanthidin-induced ventricular tachycardia, dogs (n = 7) received 200 mg/kg L-arginine. By 12-lead ECG, monophasic action potentials in left and right ventricles were recorded throughout the study. In experiment 1, guinea pigs which received 200 mg/kg or 400 mg/kg L-arginine had greater incidences of ventricular tachycardia termination (60 and 80%, respectively) than those which received 0, 25, 50, and 100 mg/kg L-arginine (0, 0, 20, and 30%, respectively), those which received L-arginine with L-NAME (0%), and those which received D-arginine (0%). In experiment 2, 5 (71%) of the dogs had successful termination of ventricular tachycardia. These findings suggest that L-arginine was effective in treating strophanthidin-induced ventricular tachycardia in vivo and that the underlying mechanism is through a NO pathway.

AB - Nitric oxide (NO) has been demonstrated to have several effects on the heart. Through the stimulation of guanylate cyclase, NO increases cyclic GMP and decreases intracellular calcium. The purpose of this study was to evaluate the effects of NO on ventricular arrhythmia induced by strophanthidin in guinea pigs and dogs. In experiment 1, after strophanthidin-induced ventricular tachycardia, guinea pigs received different doses of L-arginine (0, 25, 50, 100, 200, and 400 mg/kg; n = 10 for each dose), 200 mg/kg L-arginine combined with 100 mg/kg NG-nitro-L-arginine methylester (L-NAME, n = 10), or 200 mg/kg D-arginine (n = 10). In experiment 2, after strophanthidin-induced ventricular tachycardia, dogs (n = 7) received 200 mg/kg L-arginine. By 12-lead ECG, monophasic action potentials in left and right ventricles were recorded throughout the study. In experiment 1, guinea pigs which received 200 mg/kg or 400 mg/kg L-arginine had greater incidences of ventricular tachycardia termination (60 and 80%, respectively) than those which received 0, 25, 50, and 100 mg/kg L-arginine (0, 0, 20, and 30%, respectively), those which received L-arginine with L-NAME (0%), and those which received D-arginine (0%). In experiment 2, 5 (71%) of the dogs had successful termination of ventricular tachycardia. These findings suggest that L-arginine was effective in treating strophanthidin-induced ventricular tachycardia in vivo and that the underlying mechanism is through a NO pathway.

KW - Nitric oxide

KW - Strophanthidin

KW - Ventricular arrhythmia

UR - http://www.scopus.com/inward/record.url?scp=0035001160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035001160&partnerID=8YFLogxK

U2 - 10.1159/000056097

DO - 10.1159/000056097

M3 - Article

C2 - 11359997

AN - SCOPUS:0035001160

VL - 62

SP - 213

EP - 217

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 4

ER -